Legato Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$729K Sell
14,108
-515
-4% -$26.2K 0.07% 392
2025
Q4
$727K Sell
14,623
-7,875
-35% -$383K 0.06% 444
2025
Q3
$1.08M Buy
22,498
+1,273
+6% +$51.3K 0.12% 271
2025
Q2
$669K Hold
21,225
0.08% 381
2025
Q1
$695K Sell
21,225
-6,209
-23% -$220K 0.09% 348
2024
Q4
$992K Buy
27,434
+5,962
+28% +$210K 0.13% 299
2024
Q3
$669K Hold
21,472
0.08% 384
2024
Q2
$574K Sell
21,472
-5,933
-22% -$172K 0.08% 407
2024
Q1
$935K Buy
27,405
+5,933
+28% +$177K 0.11% 282
2023
Q4
$621K Hold
21,472
0.08% 367
2023
Q3
$592K Sell
21,472
-837
-4% -$25.5K 0.09% 359
2023
Q2
$671K Hold
22,309
0.09% 354
2023
Q1
$808K Hold
22,309
0.15% 239
2022
Q4
$796K Buy
+22,309
New +$775K 0.15% 231
2018
Q1
Sell
-21,344
Closed -$851K 208
2017
Q4
$851K Hold
21,344
0.12% 159
2017
Q3
$854K Hold
21,344
0.13% 161
2017
Q2
$920K Buy
21,344
+19,185
+889% +$683K 0.39% 71
2017
Q1
$68K Hold
2,159
0.08% 47
2016
Q4
$54.5K Buy
+2,159
New +$48.2K 0.99% 46

Other funds holding SUPN

Legato Capital Management's SUPN Position: Q1 2026 in Review

Legato Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 3.5% in Q1 2026, selling an estimated $26.2K and leaving 14,108 shares worth $729K. The position accounts for 0.07% of the portfolio, ranked #392.

Legato Capital Management first reported a position in SUPN in Q4 2016 and has held it in 19 quarters since. The position peaked at $1.08M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Legato Capital Management held 14,108 shares of Supernus Pharmaceuticals worth $729K as of Q1 2026.
  • Legato Capital Management sold 515 Supernus Pharmaceuticals shares in Q1 2026, an estimated $26.2K.
  • Supernus Pharmaceuticals made up 0.07% of Legato Capital Management's portfolio in Q1 2026, its #392 holding.
  • Legato Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
  • Legato Capital Management's Supernus Pharmaceuticals position peaked at $1.08M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.